top of page
DEMETHER
PHASE II TRIAL OF TRASTUZUMAB AND PERTUZUMAB MAINTENANCE AFTER T-DXD INDUCTION FOR HER2+ UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER
CLINICAL TRIAL DETAILS
A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER PATIENTS (DEMETHER).
DEMETHER AT CLINICALTRIALS.GOV
Breast Cancer
II
165
TBC
EU
Recruitment
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
bottom of page